SCHEMBL1284263

SCHEMBL1284263

CCOC(=O)C1=CNC(=O)NC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
KMT2A Q03164 3/20 0.41
MAPT P10636 3/20 0.41
KDM4E B2RXH2 3/20 0.41
MEN1 O00255 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
ALOX15 P16050 1/20 0.40
LMNA P02545 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.38
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
CA12 O43570 3/20 0.37
CA1 P00915 3/20 0.37
CA2 P00918 3/20 0.37
CA7 P43166 3/20 0.37
CA9 Q16790 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29093155 0.92 KMT2A (0.40) ALDH1A1KMT2AMAPTKDM4EMEN1
Hydrochloric Acid SCHEMBL8587102 0.81 CHRM3 (0.42) ALDH1A1MAPTKDM4ECYP1A2LMNA
SCHEMBL22397156 0.75 KMT2A (0.42) ALDH1A1KMT2AMAPTKDM4EMEN1
SCHEMBL9233377 0.73 CA12 (0.39) ALDH1A1KMT2AMAPTKDM4EMEN1
SCHEMBL16863288 0.72 KMT2A (0.40) ALDH1A1KMT2AMAPTKDM4EMEN1
SCHEMBL9748650 0.72 KMT2A (0.40) ALDH1A1KMT2AMAPTKDM4EMEN1
SCHEMBL28346863 0.71 MEN1 (0.39) ALDH1A1KMT2AMAPTKDM4EMEN1
SCHEMBL7425087 0.71 KDM4E (0.59) ALDH1A1KMT2AMAPTKDM4EMEN1
SCHEMBL9233379 0.71 ALDH1A1 (0.42) ALDH1A1KMT2AMAPTKDM4EMEN1
SCHEMBL9797391 0.71 KDM4E (0.48) ALDH1A1KMT2AMAPTKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116948333-A Filling modified microporous membrane and preparation method and application thereof 国家电投集团氢能科技发展有限公司 2023-10-27 CN claimed
US-20260103471-A1 CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV ASSEMBLY BIOSCIENCES INC (US) 2026-04-16 US disclosed
US-20250376478-A1 CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV ASSEMBLY BIOSCIENCES INC (US) 2025-12-11 US disclosed
US-12403142-B2 Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety CURIS, INC. (US) 2025-09-02 US disclosed
US-20250230169-A1 Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety CURIS INC (US) 2025-07-17 US disclosed
EP-4581029-A1 CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV Assembly Biosciences, Inc. (US) 2025-07-09 EP disclosed
EP-3849554-B1 COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY CURIS INC (US) 2025-01-29 EP disclosed
WO-2024226892-A1 HYDRAZONE 3H-IMIDAZO(4,5-B)PYRIDINE COMPOUNDS AND USES THEREOF Verge Analytics, Inc. (US) 2024-10-31 WO disclosed
WO-2024049760-A1 CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV ASSEMBLY BIOSCIENCES, INC. (US) 2024-03-07 WO disclosed
CN-116948333-A Filling modified microporous membrane and preparation method and application thereof 国家电投集团氢能科技发展有限公司 2023-10-27 CN disclosed
US-20090093507-A1 CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY CURIS, INC. 2009-04-09 US disclosed
US-20090093507-A1 CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY CURIS, INC. 2009-04-09 US disclosed
WO-2009036057-A1 ANTIPROLIFERATIVE AGENTS CONTAINING A ZINC BINDING MOIETY CURIS, INC. (US) 2009-03-19 WO disclosed
WO-2009036057-A1 ANTIPROLIFERATIVE AGENTS CONTAINING A ZINC BINDING MOIETY CURIS, INC. (US) 2009-03-19 WO disclosed
WO-2009036012-A1 HSP90 INHIBITORS CONTAINING A ZINC BINDING MOIETY CURIS, INC. (US) 2009-03-19 WO disclosed
WO-2009036016-A1 CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY CURIS, INC. (US) 2009-03-19 WO disclosed
WO-2009036016-A1 CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY CURIS, INC. (US) 2009-03-19 WO disclosed
US-20090076006-A1 HSP90 INHIBITORS CONTAINING A ZINC BINDING MOIETY CURIS, INC. 2009-03-19 US disclosed
US-20090076006-A1 HSP90 INHIBITORS CONTAINING A ZINC BINDING MOIETY CURIS, INC. 2009-03-19 US disclosed
US-5693611-A TREATING FUNGAL INFECTIONS, INHIBITING PARASITIC ACTIVITY, TREATING OR PREVENTING PNEUMOCYSTIS PNEUMONIA ELI LILLY AND COMPANY (US) 1997-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260103471-A1 CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV TK1, UNG, SMCHD1 ALDH1A1 3205/4885KMT2A 1471/4885MAPT 66/4885
US-20250230169-A1 Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety BAZ2A, BAZ2B, PI4KB ALDH1A1 3415/4885KMT2A 373/4885MAPT 3887/4885
US-20090093507-A1 CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY CDK3, CDKL1, CDKL3 ALDH1A1 2650/4885KMT2A 76/4885MAPT 2455/4885
US-12403142-B2 Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety PDPK1, PDCD1, PDCD1LG2 ALDH1A1 2387/4885KMT2A 1142/4885MAPT 3118/4885
US-20250376478-A1 CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV TYMP, TK1, TREH ALDH1A1 3189/4885KMT2A 3443/4885MAPT 142/4885
US-20090076006-A1 HSP90 INHIBITORS CONTAINING A ZINC BINDING MOIETY HSP90AB1, HSP90AB2P, HSP90B1 ALDH1A1 1920/4885KMT2A 897/4885MAPT 1584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.